Vertebroplasty was originally developed in France and was fi rst reported in 1987 as one strategy for percutaneously stabilizing vertebral bodies affected by a tumor (1). In 1989 the method was also shown to stabilize fractured osteoporotic vertebrae (2). Vertebroplasty was hypothetically improved in the USA by the introduction of the percutaneous balloon kyphoplasty technique (3). This is a technique of infl ating a balloon in the fractured vertebral body in order to restore the anatomy of the fractured vertebra by fi lling the created void with bone cement and reducing the fractureinduced kyphosis. Both methods instantly attracted enormous interest. A Medline literature search in October 2004 identifi ed 388 articles on " vertebroplasty " and 92 on " kyphoplasty. " A similar search in January 2010 resulted in 1398 hits for " vertebroplasty " and 1573 for " kyphoplasty. " The two techniques, the short-term clinical results, and the possible complications have all been thoroughly reported (3, 4) , but up to now there has been no scientifi c evidence-based information regarding the effi cacy of the procedures, published as prospective randomized controlled trials (RCTs). However, case reports, prospective and retrospective uncontrolled short-term observational studies, and case-control studies have consistently inferred an almost immediate relief of back pain and improved functional status after such procedures in 75 -90% of all cases (3, 4) . These conclusions are based on diverse descriptions of how pain relief was estimated and predominantly in comparison with the preoperative situation but without comparison with controls. Whether or not vertebroplasty or kyphoplasty produce better outcome than conservative treatment has so far been unknown.
Recently, however, several RCTs have increased our knowledge (5 -11). Two multicenter, randomized, double-blind, placebo-controlled trials presented in the New England Journal of Medicine -one study deriving from Australia and one from the USA, which both neglected benefi cial effects of vertebroplasty in comparison with conservative treatment in patients with osteoporotic vertebral compression fractures -have been most debated during the last few months (5, 8) .
In the Australian study, participants with one or two painful osteoporotic vertebral fractures with less than 12 months ' duration (confi rmed by magnetic resonance imaging, MRI) underwent vertebroplasty ( n ϭ 35) or sham procedures ( n ϭ 40). Participants were stratifi ed according to duration of symptoms of less than 6 weeks or 6 weeks or more, and the primary outcome (overall pain) was evaluated at 1 week and at 1, 3, and 6 months. Secondary outcomes were pain at night, pain at rest, physical function, quality of life, and perceived improvement. This study reported that there were signifi cant reductions in overall pain in both study groups but that vertebroplasty did not result in a signifi cant advantage in any measured outcome at any time compared to the controls. Furthermore, there were no benefi ts from performing the vertebroplasty in individuals with less than 6 weeks of pain (5).
In the study deriving from the Mayo Clinic, the researchers randomly assigned 131 patients who had 1 -3 painful osteoporotic vertebral compression fractures to either vertebroplasty ( n ϭ 68) or a simulated procedure without cement ( n ϭ 63). The primary outcomes were assessed using the modifi ed Roland-Morris Disability Questionnaire (RDQ) Score and the patient ratings of pain intensity during the 24 h following the operation and after 1 month. Patients were allowed to cross over to the other study group after 1 month. This study too reported that there was signifi cant improvement in the outcome measures in both the vertebroplasty and the control group and that vertebroplasty did not result in any advantage in measured outcome variables at any time compared to the controls. There was, however, a trend toward benefi cial clinical improvement in pain in the vertebroplasty group (64% versus 48%, P ϭ 0.06) after 1 month and at 3 months. The crossover rate was also higher in the control than in the vertebroplasty group (43% vs 12%, P Ͻ 0.001) (5).
A third RCT has supported the two NEJM publications, with 50 patients with acute ( Ͻ 2 weeks) and subacute (between 2 and 8 weeks) osteoporotic vertebral fractures, randomized to either vertebroplasty or conservative treatment. This study reported that reduction in pain was comparable in the two groups and that there was no signifi cant difference in the other parameters when comparing the results at inclusion and after 3 months within both groups and virtually none between the groups after 3 months (12). The authors concluded that the majority of patients with acute or subacute painful osteoporotic compression fractures in the spine will recover after a few months of conservative treatment. However, this view is opposed by other authors, who suggest that as many as 75% of patients with an osteoporosis-related vertebral fracture still have pain 1 year after the event (13 -15).
However, the RCTs that evaluated vertebroplasty have been criticized (16) . Vertebroplasty aims at internal fi xation of nonhealed osteoporotic vertebral fractures, well proven to reduce the acute and subacute pain in most fractures, but vertebral fractures usually heal within 8 weeks, whereas the edema found in MRI evaluations persists for an extended period. However, this too can be discussed, as bone healing is controversial and there is no strict defi nition as regards time limits, as to when a fracture should be defi ned as acute, subacute or a fracture with delayed union. Furthermore, the pain intensity was similar in the groups with different duration, questionning if the pain really was derived from the fracture. The study by KALLMES et al. involved only outpatients, so that inpatients hospitalized with acute fracture pain were excluded and the protocol required 4 weeks of medical therapy before enrolment was possible (8). Critics then suggest that these enrolment criteria resulted in a study on healed fractures where another source of pain should be considered, even if the pain intensity was similar to that in the acute fractures. A more appropriate selection criterion, according to the critics, would have been uncontrolled pain for less than 6 weeks, found in only 32% of the subjects in the study reported by BUCHBINDER et al. and in 44% of the subjects reported by KALLMES et al. (5, 8) . The trial by BUCHBINDER et al. had also targeted 200 patients, but only 78 were actually included over 4 years in the fi nal study, and 2 of the 4 study hospitals withdrew early after including 5 patients each. This had the result that 68% of the procedures were fi nally performed in one hospital by one radiologist. Finally, 64% of eligible patients in the Australian study and 70% in the US study declined to participate. All these concerns raise questions as regards the patient selection and the generalization of the inferences.
Some critics also suggest that the study design is inappropriate, as not all patients with a vertebral fracture benefi t from a vertebroplasty (16). In many studies, patients with maximal back pain tend to have the greatest improvement in pain score after vertebroplasty, more so than those with a lower degree of pain, and there has been concern that the level of pain in the patients in cited RCTs was lower than in most patients with vertebral fractures. However, enrolment of only patients with the most severe pain might lead to an exaggeration of treatment effi cacy due to the regression toward the mean effect. One could also question whether patients who receive an injection of an anesthetic should be regarded as unbiased controls, since local anesthetic can have effects for a period exceeding the activity of the drug. The larger crossover rates reported by KALLMES et al. as occurring in the control than in the treatment group (8) could possibly indicate dissatisfaction with the sham procedure that was not captured by pain scales. But since nearly all crossovers occurred after 1 month, the crossover should not affect the primary outcome that was evaluated after 1 month.
The effi cacy of balloon kyphoplasty in the treatment of vertebral osteoporotic fractures has now also been evaluated in one multicenter RCT, including 149 kyphoplasty-treated patients and 151 nonsurgically treated patients with 1 -3 acute vertebral fractures (11). The primary outcome was the difference in change from baseline to 1 month assessed by SF-36 and 12 months in quality of life evaluation. Both groups improved in quality of life, the kyphoplasty group by a mean 7.2 points (95% CI 5.7 -8.8) and the nonsurgical care group by a mean 2.0 points (95% CI 0.4 -3.6), a group difference of a mean 5.2 points (95% CI 2.9 -7.4). The authors then inferred that balloon kyphoplasty is an effective procedure for patients with acute vertebral fractures (11). However, substantial improvement was found in both the operated and the nonoperated group, and even if there was a group difference in the outcome score, it ought to be discussed whether the difference is of clinical relevance. In addition, during follow-up, 21 (14%) participants in the kyphoplasty group had new clinical vertebral fractures, in several cases rendering a need for new surgical interventions.
There are also few reports that directly compare percutaneous balloon kyphoplasty and percutaneous vertebroplasty. This ought to be done as there could be advantages in the kyphoplasty method, since it aims to restore the normal anatomy of the fractured vertebra and to reduce the kyphosis in the injured region (17). By infl ating a balloon in the fractured vertebral body, the kyphoplasty method seeks to recreate the original shape of the compressed vertebral body, before the cement fi xation is advocated. However, it has so far been diffi cult to show any clinical advantages that justify the higher cost of kyphoplasty compared with the vertebroplasty technique. Now there is also direct comparison between the methods, in one RCT for 6 months that included 100 patients, where the authors reported that in all terms of clinical outcome there was no real difference between the treatment groups when using either of the two methods (9) .
It is not only important to evaluate whether there is a difference in the clinical outcome between surgical and nonsurgical treatment, however. All new methods should also be assessed as regards the cost in relation to quality of life. The term cost per QUALY is then often used, a term including cost per gain in quality-adjusted years of life. There has been a publication dealing with this question, mostly based on the assumption or model that already reported shortterm effects achieved by vertebroplasty and kyphoplasty remain in the long term (11). Using " willingness to pay " (WTP) of 600 000 Swedish crowns, some of these models report that the methods could be cost-effective (18). However, there is a need for more studies, also with long-term follow-up including both clinical outcome and costs for society, before we can draw stricter conclusions as regards the costeffectiveness of the methods.
In general we should discontinue a treatment when there is convincing evidence that it provides little or no effect. The reported RCTs on vertebroplasty (5, 7, 8, 12) provide the best evidence we have to date regarding the effi cacy of vertebroplasty for the treatment of osteoporotic vertebral compression fractures. The fi nding of improvement in pain in both the intervention and the control groups and the lack of benefi t in the intervention versus the control group seem to refl ect the benign natural history of pain development in vertebral compression fractures in the elderly. It must then be regarded as questionable to offer patients an intervention that is no more effective, is more expensive, and possibly more dangerous than placebo (5). Most patients, when receiving this information, will probably choose the less invasive and less risky procedure. The RCTs should once more remind us to be cautious in using treatments based on data with a lower level of evidence. Case reports and observational studies are often biased toward overestimating treatment benefi ts. Vertebroplasty appears to confer no benefi t over a sham procedure or nonoperative care, and it includes adverse risks associated with the operation. In contrast to this, one RCT has shown signifi cant differences in the quality of life score after 1 month in a group operated by balloon kyphoplasty in comparison with one group subjected to nonsurgical care (11). Whether the difference represents not only a statistically significant difference but also a clinically relevant difference should be evaluated in future studies.
In conclusion, lack of evidence of effi cacy when advocating vertebroplasty in the treatment of osteoporotic vertebral fractures is stronger than the proof of effi cacy when using kyphoplasty. The results of published RCTs should lead to the discontinuation of vertebroplasty as a general treatment modality for vertebral compression fractures with persisting pain in the elderly osteoporotic patient, while balloon kyphoplasty ought to be evaluated in further studies before more defi nite recommendations can be put forward.
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